Alpha-1 Proteinase Inhibitor (Aralast NP, Glassia, Prolastin-C, Zemaira)

Covered: IV alpha1‑proteinase inhibitors (Aralast NP, Glassia, Prolastin‑C, Zemaira) are covered for chronic augmentation/maintenance in adults with clinically evident emphysema due to severe congenital AAT deficiency and for panniculitis as an accepted compendial off‑label use; other indications are excluded. Key requirements: approvals are for 12 months, recommended dosing 60 mg/kg IV weekly, emphysema patients must have baseline AAT <11 µmol/L (<80 mg/dL) and be current nonsmokers, and documentation of diagnosis, labs, nonsmoker status, adult age and weight (for dosing) is required.

"Aralast NP, Glassia, Prolastin-C and Zemaira are an alpha1-proteinase inhibitor indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe ..."

Sign up to see full coverage criteria, indications, and limitations.